rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis

References

• World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022. licence: cc bY-Nc-sa 3.0 iGo.
   Google Scholar
• Zaw MT, Emran NA, Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health. 2018;11(5):605–610. doi:10.1016/j.jiph.2018.04.005
   PubMed Web of Science ®Google Scholar
• Lee SS, Meintjes G, Kamarulzaman A, Leung CC. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons. Respirology. 2013;18(6):912–922. doi:10.1111/resp.12120
   Web of Science ®Google Scholar
• Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet. 2014;53(6):489–507. doi:10.1007/s40262-014-0144-3
   PubMed Web of Science ®Google Scholar
• Jo KW, Ji W, Hong Y, et al. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med. 2013;107:292–297. doi:10.1016/j.rmed.2012.10.021
   Web of Science ®Google Scholar
• Lee H, Ahn S, Hwang NY, et al. Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis. Int J Infect Dis. 2017;65:135–141. doi:10.1016/j.ijid.2017.10.013
   PubMed Web of Science ®Google Scholar
• Aristoff PA, Garcia GA, Kirchhoff PD, Showalter HD. Rifamycins--obstacles and opportunities. Tuberculosis. 2010;90:94–118. doi:10.1016/j.tube.2010.02.001
   PubMed Web of Science ®Google Scholar
• Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15:1485–9, i. doi:10.5588/ijtld.11.0068
   PubMed Web of Science ®Google Scholar
• Jagielski T, Bakula Z, Brzostek A, et al. Characterization of mutations conferring resistance to rifampin in Mycobacterium tuberculosis clinical strains. Antimicrob Agents Chemother. 2018;62(10). doi:10.1128/AAC.01093-18
   Web of Science ®Google Scholar
• Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55(5):2032–2041. doi:10.1128/AAC.01550-10
   PubMed Web of Science ®Google Scholar
• Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014;52(6):2157–2162. doi:10.1128/JCM.00691-14
   PubMed Web of Science ®Google Scholar
• Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother. 1996;40(4):1053–1056. doi:10.1128/AAC.40.4.1053
   Web of Science ®Google Scholar
• Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(2):893–900. doi:10.1128/AAC.01024-12
   PubMed Web of Science ®Google Scholar
• Farhat MR, Sixsmith J, Calderon R, Hicks ND, Fortune SM, Murray M. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2019;74(6):1477–1483. doi:10.1093/jac/dkz048
   Web of Science ®Google Scholar
• Schon T, Jureen P, Chryssanthou E, et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint art fact? J Antimicrob Chemother. 2013;68(9):2074–2077. doi:10.1093/jac/dkt150
   Web of Science ®Google Scholar
• Rukasha I, Said HM, Omar SV, et al. Correlation of rpoB mutations with minimal inhibitory concentration of rifampin and rifabutin in Mycobacterium tuberculosis in an HIV/AIDS endemic setting, South Africa. Front Microbiol. 2016;7:1947. doi:10.3389/fmicb.2016.01947
   Web of Science ®Google Scholar
• Whitfield MG, Warren RM, Mathys V, et al. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother. 2018;73(10):2667–2674. doi:10.1093/jac/dky248
   Web of Science ®Google Scholar
• Berrada ZL, Lin SY, Rodwell TC, et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis. 2016;85(2):177–181. doi:10.1016/j.diagmicrobio.2016.01.019
   PubMed Web of Science ®Google Scholar
• Li MC, Lu J, Lu Y, et al. rpoB mutations and effects on rifampin resistance in Mycobacterium tuberculosis. Infect Drug Resist. 2021;14:4119–4128. doi:10.2147/IDR.S333433
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical Report on Critical Concentrations for Drug Susceptibility Testing of Isoniazid and the Rifamycins (Rifampicin, Rifabutin and Rifapentine). Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Wood GL. CLSI Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomy Cetes. 1st ed. CLSI; 2018:M62.
   Google Scholar
• Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDR plus for patient selection for a Tuberculosis clinical trial. J Clin Microbiol. 2011;49(8):2827–2831. doi:10.1128/JCM.00138-11
   Web of Science ®Google Scholar
• Di Tanna GL, Khaki AR, Theron G, et al. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Glob Health. 2019;7(2):e191–e199. doi:10.1016/S2214-109X(18)30458-3
   Web of Science ®Google Scholar
• Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for Tuberculosis. N Engl J Med. 2017;377(11):1043–1054. doi:10.1056/NEJMoa1614915
   PubMed Web of Science ®Google Scholar
• Wi YM, Greenwood-Quaintance KE, Brinkman CL, Lee JYH, Howden BP, Patel R. Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations. Int J Antimicrob Agents. 2018;51(5):670–677. doi:10.1016/j.ijantimicag.2017.12.019
   Web of Science ®Google Scholar
• Chen HY, Yu MC, Huang WL, et al. Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis. J Clin Microbiol. 2012;50:2085–2088. doi:10.1128/JCM.00652-12
   Web of Science ®Google Scholar
• Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79:3–29. doi:10.1054/tuld.1998.0002
   PubMedGoogle Scholar
• Rothman-Denes LB. Structure of Escherichia coli RNA polymerase holoenzyme at last. Proc Natl Acad Sci USA. 2013;110(49):19662–19663. doi:10.1073/pnas.1320604110
   Web of Science ®Google Scholar
• Goldstein BP. Resistance to rifampicin: a review. J Antibiot. 2014;67(9):625–630. doi:10.1038/ja.2014.107
   PubMed Web of Science ®Google Scholar
• Xu G, Liu H, Jia X, Wang X, Xu P. Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: the phenomenon of drug resistance is complex. Tuberculosis. 2021;128:102083. doi:10.1016/j.tube.2021.102083
   PubMed Web of Science ®Google Scholar
• WHO catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance; 2021. Available from: https://apps.who.int/iris/handle/10665/341981. Accessed November 21, 2022.
   Google Scholar
• Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50(6):1701354. doi:10.1183/13993003.01354-2017
   PubMed Web of Science ®Google Scholar
• Shea J, Halse TA, Kohlerschmidt D, et al. Low-level rifampin resistance and rpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York. J Clin Microbiol. 2021;59(4):e01885–e01920.
   Web of Science ®Google Scholar
• Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother. 2009;53(8):3181–3189. doi:10.1128/AAC.01577-08
   PubMed Web of Science ®Google Scholar